OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.
伦敦和纽约州纽约，2024年4月2日——OKYO Pharma Limited（纳斯达克股票代码：OKYO），一家处于临床阶段的生物制药公司，开发创新的眼部疗法，用于治疗价值数十亿美元的市场炎症性干眼病（DED）和前眼节疾病，包括神经病理性角膜疼痛（NCP），一种与疼痛有关但未获美国食品药品管理局批准的疗法的眼部疾病即将在美国白内障学会合作伙伴会议 Eyecelerator 2024 上发布干眼病 OK-101 二期数据以及将于2024年4月4日在马萨诸塞州波士顿举行的屈光手术（ASCRS）年会。
Eyecelerator Presenting Company Showcase – OKYO Pharma Presentation Details
Eyecelerator 展示公司展示 — OKYO Pharma 演示详情
Date: Thursday, April 4, 2024
日期：2024 年 4 月 4 日，星期四
Time: 1:00 – 2:30PM ET
时间：美国东部时间下午 1:00 — 2:30
Location: Omni Boston Hotel at the Seaport – Level 2
地点：海港波士顿全方位酒店 — 2 层
Ensemble Ballroom C, Breakout 1
Ensemble 宴会厅 C，分组会议 1
Presenter: Gary Jacob, PhD, Chief Executive Officer
主持人：加里·雅各布博士，首席执行官
About Eyecelerator
关于 Eyecelerator
Eyecelerator is a partnership between the American Academy of Ophthalmology and ASCRS to accelerate ophthalmic innovation through next-generation business conferences. Held the Thursday before each partner society's annual meeting, Eyecelerator spurs innovation by connecting the scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who support their success. Eyecelerator conferences provide a full day of KOL-driven programs highlighting industry advancements, investment trends, and innovative new products disrupting eye care. The conferences also provide valuable opportunities to network and explore new market potentials and the occasion for dozens of companies to present their novel clinical treatments and emerging technologies that are shaping the future of ophthalmology.
Eyecelerator是美国眼科学会和ASCRS之间的合作伙伴关系，旨在通过下一代商务会议加速眼科创新。Eyecelerator在每个伙伴协会年会之前的星期四举行，通过将推进眼科护理的科学人才和企业家与支持其成功的使命驱动型投资者和商业伙伴联系起来，促进创新。Eyecelerator会议提供一整天由KOL主导的项目，重点介绍行业进步、投资趋势和颠覆眼部护理的创新新产品。这些会议还为交流和探索新的市场潜力提供了宝贵的机会，也为数十家公司提供了展示他们塑造眼科未来的新型临床疗法和新兴技术的机会。
About OKYO
关于 OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
东洋制药有限公司（纳斯达克股票代码：OKYO）是一家临床阶段的生物制药公司，开发治疗DED和NCP的创新疗法，普通股在纳斯达克资本市场上市交易。OKYO 专注于发现和开发用于治疗炎症 DED 和眼痛的新分子。除了最近完成的二期 DED 试验外，OKYO 还计划启动 OK-101 的 2 期试验，以治疗患有这种虚弱性疾病的患者的 NCP。欲了解更多信息，请访问 www.okyopharma.com。
Enquiries:
查询：
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
| OKYO 制药有限公司 | Gary S. Jacob，首席执行官 | 917-497-7560 |
| 业务发展与投资者关系 | 保罗斯宾塞 | +44 (0) 20 7495 2379 |